CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 186 enrolled
Drug / intervention
Arctic Front Advance Cardiac CryoAblation Catheterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03012841
NCT03012841N/ACompleted
CompareCT.gov

STOP Persistent AF

Medtronic Cardiac Ablation Solutions·interventional·Posted Jan 6, 2017·Updated Feb 13, 2025

In Brief

A clinical study evaluating Arctic Front Advance Cardiac CryoAblation Catheter for Atrial Fibrillation. Completed, enrolled 186 participants across 25 sites in 3 countries.

Detailed Summary

To demonstrate safety and effectiveness of the Arctic Front Advance™ and Freezor MAX® Cardiac CryoAblation Catheters for the treatment of drug refractory recurrent symptomatic persistent atrial fibrillation (AF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesCanada, Japan, United States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 6, 2017
Enrollment StartMar 2, 2017
Primary CompletionAug 13, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.5 years ago

Interventions

Arctic Front Advance Cardiac CryoAblation Catheterdevice

Cryoablation